Internal Medicine, Nephrology · Hinesville, GA
NPI
1104833698
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
6
Hospital affiliations
455 S Main St, Ste 201
Hinesville, GA, 31313
Phone (912) 877-6822
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
21,399 services
Medicare patients, 2024
1,570
Average age 74
Drug cost, 2024
$5.6M
9,763 prescriptions
Company payments, 2025
$1,883
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nizar Eskandar was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 2,221 times for 1,060 patients. In total Nizar Eskandar billed 21,399 services in 89 codes, and Medicare paid $1.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-11-23.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,221 | 1,060 | $11.57 | $26K |
| 99214 Office E&M - Established | Office | 2,117 | 963 | $83.40 | $177K |
| 99233 Hospital E&M - Subsequent | Facility | 2,021 | 335 | $85.04 | $172K |
| 99232 Hospital E&M - Subsequent | Facility | 1,425 | 261 | $56.55 | $81K |
| 36415 Venipuncture Blood Collection | Office | 1,019 | 571 | $8.51 | $8,670 |
| 80053 Clinical Chemistry | Office | 715 | 446 | $10.31 | $7,371 |
| 85025 Blood Count | Office | 644 | 428 | $7.53 | $4,849 |
| 83735 Clinical Chemistry | Office | 621 | 407 | $6.50 | $4,039 |
| 82570 Clinical Chemistry | Office | 599 | 411 | $5.05 | $3,022 |
| 84100 Clinical Chemistry | Office | 599 | 400 | $4.61 | $2,764 |
| 84156 Clinical Chemistry | Office | 580 | 398 | $3.57 | $2,073 |
| 82043 Clinical Chemistry | Office | 549 | 380 | $5.61 | $3,079 |
| 81015 Clinical Chemistry | Office | 549 | 373 | $2.93 | $1,607 |
| 99223 Hospital E&M - Initial | Facility | 444 | 354 | $126.48 | $56K |
| 83970 Clinical Chemistry | Office | 417 | 315 | $40.13 | $17K |
By year: 2022 $984K for 18,054 services; 2023 $1.2M for 16,655 services; 2024 $1.9M for 21,399 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,019 | 571 | $8.51 | $8,670 |
| 80053 Clinical Chemistry | 715 | 446 | $10.31 | $7,371 |
| 85025 Blood Count | 644 | 428 | $7.53 | $4,849 |
| 83735 Clinical Chemistry | 621 | 407 | $6.50 | $4,039 |
| 84100 Clinical Chemistry | 599 | 400 | $4.61 | $2,764 |
| 82570 Clinical Chemistry | 599 | 411 | $5.05 | $3,022 |
| 84156 Clinical Chemistry | 580 | 398 | $3.57 | $2,073 |
| 82043 Clinical Chemistry | 549 | 380 | $5.61 | $3,079 |
| 81015 Clinical Chemistry | 549 | 373 | $2.93 | $1,607 |
| 83970 Clinical Chemistry | 417 | 315 | $40.13 | $17K |
Medicare prescription drug claims, 2024
In 2024, the drug Nizar Eskandar prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 714 prescriptions and refills. In total Nizar Eskandar wrote 9,763 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 714 | 1,355 | 214 | $748K |
| Amlodipine Besylate Generic | 553 | 1,359 | 181 | $3,124 |
| Furosemide Generic | 529 | 1,374 | 212 | $2,926 |
| Losartan Potassium Generic | 397 | 1,043 | 147 | $3,325 |
| Olmesartan Medoxomil Generic | 336 | 832 | 114 | $4,192 |
| Carvedilol Generic | 295 | 733 | 104 | $1,863 |
| Spironolactone Generic | 258 | 646 | 101 | $2,614 |
| Hydralazine Hcl Generic | 254 | 595 | 79 | $3,458 |
| Allopurinol Generic | 235 | 581 | 81 | $2,052 |
| Chlorthalidone Generic | 223 | 573 | 77 | $3,389 |
| Levothyroxine Sodium Generic | 218 | 459 | 60 | $1,661 |
| Mounjaro Tirzepatide | 198 | 228 | 37 | $237K |
| Lisinopril Generic | 167 | 404 | 57 | $1,142 |
| Bumetanide Generic | 162 | 323 | 65 | $7,455 |
| Valsartan Generic | 160 | 402 | 60 | $5,224 |
Brand drugs: 2,347 claims; generic drugs: 7,392 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nizar Eskandar $1,883 ($1,883 in general payments such as food, travel and fees) from 19 companies. The largest payer was Otsuka America Pharmaceutical, Inc. with $441.
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. 4578.T | 12 | $441 |
| Amgen Inc. AMGN | 16 | $283 |
| Travere Therapeutics, Inc. TVTX | 13 | $249 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $139 |
| Averitas Pharma Inc. | 4 | $87.92 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $87.84 |
| Merck Sharp & Dohme LLC MRK | 5 | $83.04 |
| Mallinckrodt Hospital Products Inc. | 4 | $82.08 |
| ANI Pharmaceuticals, Inc. ANIP | 3 | $65.54 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $59.58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.